Compare ORBS & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORBS | OCGN |
|---|---|---|
| Founded | 1966 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.0M | 474.8M |
| IPO Year | 2022 | 2014 |
| Metric | ORBS | OCGN |
|---|---|---|
| Price | $0.79 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.17 |
| AVG Volume (30 Days) | ★ 15.0M | 6.2M |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,820,779.00 | N/A |
| Revenue This Year | N/A | $12.33 |
| Revenue Next Year | N/A | $10.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $0.78 |
| 52 Week High | $7.17 | $2.73 |
| Indicator | ORBS | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.59 | 28.98 |
| Support Level | $0.78 | N/A |
| Resistance Level | $1.22 | $1.12 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 20.16 | 2.81 |
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").